Before the disease re-evaluation one year after allo-HSCT, he spent two weeks in Malta where he performed dives up to 25 meters deep.
The clinical evaluation was unremarkable with full blood count parameters within the range of normality.
The bone marrow biopsy showed mostly necrotic bone and bone marrow with and focal acellular marrow with serous atrophy (Figure 1A-C). No hematopoietic cells were seen. Immuno-histochemistry showed negative CD34, CD117, E-cadherin, MPO, and CD61; Alcian blue highlighted a small area of serous atrophy (Figure 1D).
This case illustrates the need for careful review of clinical history, including recreational activities, when interpreting post-transplant biopsy results. Divers, especially those with a history of dysbaric conditions, present unique diagnostic challenges. The finding of bone marrow necrosis in this patient underscores the complexity of post-transplant care and the need for interdisciplinary communication.
The importance of intertalk between the hematopathologist and the clinician cannot be overstated. Detailed clinical information, including the patient's activities and medical history, is essential for accurate diagnosis and appropriate management. In this case, the absence of hematopoietic cells and the presence of necrotic bone with serous atrophy suggested a non-malignant aetiology, which was corroborated by the patient's diving history and prior avascular necrosis.
This case also highlights the broader implications of allo- HSCT in patients with MDS/MPN with neutrophilia. While the procedure offers a potential cure, the long-term success and quality of life post-transplant can be influenced by a range of factors beyond the immediate transplant-related risks. Regular follow-up and comprehensive assessments, incorporating both hematologic and non-hematologic parameters, are essential for optimizing patient outcomes.
In conclusion, this case emphasizes the multifaceted nature of post-allo-HSCT care. The occurrence of bone marrow necrosis in a patient with a history of deep diving activities underscores the need for a holistic approach to patient management. Interdisciplinary collaboration and thorough clinical evaluation are critical for distinguishing between transplant-related complications and external factors, ultimately guiding appropriate treatment strategies and ensuring the best possible outcomes for patients undergoing allo-HSCT.
Conflict of Interest
The authors declare that they have no conflict of interest for this
article.
Authorship Contributions
Concept: HT, DA, LBS, Design: HT, LBS, Data collection or
processing: HT, LBS, Analysis or Interpretation: HT, DA, LBS,
Literature search: HT, Writing: HT, DA, LBS, Approval: HT, DA,
LBS.
1) Avenoso D, Mehra V, Slonim LB, de Farias M, Alshehri H, Bouziana
S, Krishnamurthy P, Kulasekararaj A, Dazzi F, Wood H, Kenyon
M, Leung YT, Anteh S, Shah MN, Hannah G, Serpenti F,
Gameil A, Bourlon C, Dragoi OD, Pagliuca A, Potter V. Myeloablative
Dose of Busulfan and Fludarabine Combined with In Vivo
T Cell Depletion Is Safe and Effective Conditioning for Acute Myeloid
Leukemia and Myelodysplastic Syndrome Patients. Transplant
Cell Ther. 2023;29(11):698.e1-698.e6.
2) Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon
C, de la Camara R, Dolstra H, Duarte RF, Glass B, Greco
R, Lankester AC, Mohty M, Neven B, de Latour RP, Pedrazzoli P,
Peric Z, Yakoub-Agha I, Sureda A, Kröger N; European Society
for Blood and Marrow Transplantation (EBMT). Indications for
haematopoietic cell transplantation for haematological diseases,
solid tumours and immune disorders: current practice in Europe,
2022. Bone Marrow Transplant. 2022;57(8):1217-39.
3) Breccia M. Atypical CML: diagnosis and treatment. Hematology
Am Soc Hematol Educ Program. 2023;2023(1):476-82.
4) Gotlib J. How I treat atypical chronic myeloid leukemia. Blood.
2017;129(7):838-45.